


Volume 350S, September 2021

ISSN 0378-4274
S0378-4274(21)X0014-8

Publication of this abstract supplement was supported by EUROTOX
(Federation of European Toxicologists and European Societies of Toxicology)

Toxicology Letters

Official Journal of EUROTOX



EUROTOX 2021
VIRTUAL CONGRESS
27 SEPTEMBER – 1 OCTOBER 2021

ABSTRACTS of the 56th Congress of the European Societies of Toxicology (EUROTOX 2021)
TOXICOLOGY OF THE NEXT GENERATION
virtual congress, 27th of September – 1st of October 2021

Aims and Scope

Toxicology Letters serves as a multidisciplinary forum for research in all areas of toxicology. The prime aim is rapid publication of research letters with sufficient importance, novelty and breadth of interest. In addition to research letters, papers presenting hypotheses and commentaries addressing current issues of immediate interest to other investigators are invited. Mini-reviews in various areas of toxicology will also be published. A new feature is the provision of a forum for the discussion and interpretation of data published in the journal. Clinical, occupational and safety evaluation, legal, risk and hazard assessment, impact on man and environment studies of sufficient novelty to warrant rapid publication will be considered.

Publication information: Toxicology Letters (ISSN 0378-4274). For 2019, volumes 301–318 are scheduled for publication. Subscription prices are available upon request from the Publisher or from the Elsevier Customer Service Department nearest you or from this journal's website (<http://www.elsevier.com/locate/toxlet>). Further information is available on this journal and other Elsevier products through Elsevier's website: (<http://www.elsevier.com>).

Subscriptions are accepted on a prepaid basis only and are entered on a calendar year basis. Issues are sent by standard mail (surface within Europe, air delivery outside Europe). Priority rates are available upon request. Claims for missing issues should be made within six months of the date of dispatch.

Language (Usage and Editing services)

Please write your text in good English (American or British usage is accepted, but not a mixture of these). Authors who feel their English language manuscript may require editing to eliminate possible grammatical or spelling errors and to conform to correct scientific English may wish to use the English Language Editing service available from Elsevier's WebShop <http://webshop.elsevier.com/languageediting/> or visit our customer support site <http://service.elsevier.com> for more information.

Illustration services

Elsevier's WebShop (<http://webshop.elsevier.com/illustrationservices>) offers Illustration Services to authors preparing to submit a manuscript but concerned about the quality of the images accompanying their article. Elsevier's expert illustrators can produce scientific, technical and medical-style images, as well as a full range of charts, tables and graphs. Image 'polishing' is also available, where our illustrators take your image(s) and improve them to a professional standard. Please visit the website to find out more.

Orders, claims, and journal inquiries: please contact the Elsevier Customer Service Department nearest you:

St. Louis: Elsevier Customer Service Department, 3251 Riverport Lane, Maryland Heights, MO 63043, USA; phone: (877) 8397126 [toll free within the USA]; (+1) (314) 4478878 [outside the USA]; fax: (+1) (314) 4478077; e-mail: JournalCustomerService-usa@elsevier.com

Oxford: Elsevier Customer Service Department, The Boulevard, Langford Lane, Kidlington OX5 1GB, UK; phone: (+44) (1865) 843434; fax: (+44) (1865) 843970; e-mail: JournalsCustomerServiceEMEA@elsevier.com

Tokyo: Elsevier Customer Service Department, 4F Higashi-Azabu, 1-Chome Bldg, 1-9-15 Higashi-Azabu, Minato-ku, Tokyo 106-0044, Japan; phone: (+81) (3) 5561 5037; fax: (+81) (3) 5561 5047; e-mail: JournalsCustomerServiceJapan@elsevier.com

Singapore: Elsevier Customer Service Department, 3 Killiney Road, #08-01 Winsland House I, Singapore 239519; phone: (+65) 63490222; fax: (+65) 67331510; e-mail: JournalsCustomerServiceAPAC@elsevier.com

© 2019 Elsevier Ireland Ltd.

This journal and the individual contributions contained in it are protected under copyright, and the following terms and conditions apply to their use in addition to the terms of any Creative Commons or other user license that has been applied by the publisher to an individual article:

Photocopying

Single photocopies of single articles may be made for personal use as allowed by national copyright laws. Permission is not required for photocopying of articles published under the CC BY license nor for photocopying for non-commercial purposes in accordance with any other user license

applied by the publisher. Permission of the publisher and payment of a fee is required for all other photocopying, including multiple or systematic copying, copying for advertising or promotional purposes, resale, and all forms of document delivery. Special rates are available for educational institutions that wish to make photocopies for non-profit educational classroom use.

Derivative Works

Users may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions or companies. Other than for articles published under the CC BY license, permission of the publisher is required for resale or distribution outside the subscribing institution or company.

For any subscribed articles or articles published under a CC BY-NC-ND license, permission of the publisher is required for all other derivative works, including compilations and translations.

Storage or Usage

Except as outlined above or as set out in the relevant user license, no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the publisher.

Permissions

For information on how to seek permission visit www.elsevier.com/permissions or call: (+44) 1865 843830 (UK) / (+1) 215 239 3804 (USA).

Author rights

Author(s) may have additional rights in their articles as set out in their agreement with the publisher (more information at <http://www.elsevier.com/authorsrights>).

Notice

No responsibility is assumed by the publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made.

Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer.

Sponsored Supplements and/or Commercial Reprints: For more information please contact Elsevier Life Sciences Commercial Sales, Radarweg 29, 1043 NX Amsterdam, The Netherlands; phone: (31) (20) 485 2939/2059; e-mail: LSCS@elsevier.com

Advertising information: If you are interested in advertising or other commercial opportunities please e-mail Commercialsales@elsevier.com and your inquiry will be passed to the correct person who will respond to you within 48 hours.

Funding body agreements and policies

Elsevier has established agreements and developed policies to allow authors whose articles appear in journals published by Elsevier, to comply with potential manuscript archiving requirements as specified as conditions of their grant awards. To learn more about existing agreements and policies please visit <http://www.elsevier.com/fundingbodies>

Author inquiries

You can track your submitted article at <http://www.elsevier.com/track-submission>. You can track your accepted article at <http://www.elsevier.com/trackarticle>. You are also welcome to contact Customer Support via <http://service.elsevier.com>

The paper used in this publication meets the requirements of ANSI/ NISO Z39.48-1992 (Permanence of Paper)

Printed by Henry Ling Ltd., Dorchester, UK

For a full and complete Guide for Authors, please go to:
<http://www.elsevier.com/locate/toxlet>

Toxicology Letters

*An International Journal for the Rapid Publication of Short Reports on all Aspects
of Toxicology Especially Mechanisms of Toxicity*

Editor-in-Chief

Angela Mally

Associate Editors

Timothy Gant

Scott Garrett

Emanuela Testai

Abstracts of the
56th Congress of the European Societies of Toxicology
(EUROTOX 2021)

TOXICOLOGY OF THE NEXT GENERATION

Virtual Congress, 27th September – 1st October 2021



ELSEVIER

Amsterdam—Boston—London—New York—Oxford—Paris—Philadelphia—San Diego—St. Louis

Toxicology Letters

Editor-in-Chief

Angela Mally, Julius Maximilians University Würzburg Department of Toxicology, Versbacher Straße 9, 97078, Würzburg, Germany, Fax: +49 931 201 48865

Associate Editors

T. Gant, Kings College London Environmental Research Group, London, United Kingdom

S. Garrett, University of North Dakota School of Medicine and Health Sciences, 501 N. Columbia Road Stop 9037, ND 58202, Grand Forks, North Dakota, United States of America

E. Testai, National Institute of Health Laboratory of Comparative Toxicology and Ecotoxicology, Roma, Italy

Editorial Board

J.T. Ahokas, Melbourne, Australia

B. Akingbemi, Auburn, AL, USA

L. Aleksunes, Piscataway, NJ, USA

S. Benoff, Manhasset, NY, USA

M.J. Campen, Albuquerque, NM, USA

Z. Cao, Beijing, China

W.M. Caudle, Atlanta, GA, USA

J.N.M. Commandeur, Amsterdam, The Netherlands

M.L. Cunningham, Research Triangle Park, NC, USA

V. Cuomo, Rome, Italy

M.L.Z. Dagli

B. Delclos, Jefferson, USA

L. Dencker, Uppsala, Sweden

D. Dietrich, Konstanz, Germany

J.L. Domingo, Reus, Spain

N. Filipov, Athens, GA, USA

J. Filser, Neuherberg, Germany

A.-M. Florea, Düsseldorf, Germany

S. Garrett, Grand Forks, ND, USA

D.S. Gupta, Calcutta, West Bengal, India

E.S. Harpur, Alnwick, UK

M. Ikeda, Kyoto, Japan

M. Iscan, Ankara, Turkey

D. Jenssen, Stockholm, Sweden

L. Klotz, Edmonton, AB, USA

Y. Li, NC 27506, USA

J. Liesivuori, Turku, Finland

D. Lison, Brussels, Belgium

B. Liu, Gainesville, FL, USA

F. de Matteis, Sutton, UK

G.W. Miller, Atlanta, GA, USA

H. Naranmandura, Hangzhou, Zhejiang, China

P. Preziosi, Rome, Italy

X. Qin, Newark, NJ, USA

J. Ren, Laramie, WY, USA

S. Sahu, Washington DC, USA

C.M. Sayes, Research Triangle Park, NC, USA

S. Somji, Grand Forks, ND, USA

H. Stopper, Würzburg, Germany

E. Testai, Rome, Italy

B. Thrall, Richland, WA, USA

A.M. Tsatsakis, Heraklion, Greece

J. Tuomisto, Kuopio, Finland

M. van den Berg, Utrecht, Netherlands

L.S. Van Winkle, Davis, CA, USA

E. Vilanova, Alicante, Spain

M. Wilhelm, Bochum, Germany

M. Wilks, Basel, Switzerland

M.A. Williams, Maryland, USA

H. Yin, Cambridge, MA, USA

Y. Zhao, Shreveport, LA, USA

H. Zhu, Lillington, NC, USA

Abstracts of the
56th Congress of the European Societies of Toxicology
(EUROTOX 2021)
TOXICOLOGY OF THE NEXT GENERATION

Virtual Congress, 27th September – 1st October 2021

Preface

Continuing Education Courses (CECs)

- CEC01 Thyroid hormones, brain development and toxicity testing
- CEC02: Advances in conducting systematic reviews for chemical assessment: automation, uncertainty assessment and synthesis
- CEC03: Lessons learned and future directions for toxicology in water safety and security
- CEC04: Inflammation as a mediator of toxic responses
- CEC05: Nanotoxicology
- CEC06: Toxicity assessment in drug development

Invited sessions

- EUROTOX/SOT Debate
Bo Holmstedt Memorial Fund Lecture
SOT Merit Award Lecture 1
SOT Merit Award Lecture 2
HESI CITE Lecture
- D EUROTOX-SOT Debate:
Individualized toxicity is the future
of risk assessment
- B Bo Holmstedt Memorial Fund Lecture:
Context matters: Next generation insights on
the chemistry of DNA damage and mutation
- SOT 1 SOT Merit Award Lecture 1:
Unraveling the molecular mechanisms
of cannabinoid-mediated immune modulation
and cannabinoid receptor 2 as a putative
therapeutic target
- SOT 2 SOT Merit Award Lecture 2:
The exciting challenge of working
in regulatory toxicology
- H HESI CITE Lecture:
Linking primary mechanisms of environmentally
induced neurotoxicity to human neurological
disease relevance

Sessions

- Session 01: The effect of chemicals on the gut microbiota: is it the cause of all problems?
- Session 02: In vitro organotypic models for predicting the toxicity of chemicals or drugs
- Session 03: Artificial intelligence and machine learning in chemical risk assessment
- Session 03 A: EAPCCT symposium on COVID-19 and the toxicity of therapeutic drugs and vaccines
- Session 04: Personalized nano-immunotoxicology for the workplace
- Session 05: The use of minipigs in juvenile studies in an evolving regulatory landscape
- Session 06: Human induced pluripotent stem cell (iPSC)-based test systems for future mechanism-based chemical safety testing
- Session 07: Setting the European Environment and Health Research Agenda, 2020-2030: the HERA project
- Session 08: Back-translation from clinical outcomes, how did investigative toxicology, modelling and simulation actually perform?
- Session 09: Increasing confidence in non-animal approaches for regulatory decision-making
- Session 10: Computational modeling of AOP networks to assist risk assessment of chemicals
- Session 11: Emerging tools for the investigation and prediction of liver toxicity
- Session 12: Application of high throughput transcriptomics in mechanism-based chemical safety assessment
- Session 13: Modes of action in non-genotoxic carcinogenesis
- Session 14: New approaches using in vitro assays and 3D models can improve prediction of immune reactions to xenobiotics
- Session 15: Impact of climate change on food safety
- Session 16: Human microengineered organs-on-chips: advancing regulatory science through innovation
- Session 17: Designing toxicology studies to support development of cell-based therapies

-
- Session 18: Mechanistic toxicology as the basis for modelling and prediction of organ-specific toxicity
- Session 19: Can we panelize seizure?
- Session 20: Modernizing cancer risk assessment: beyond the bioassay
- Session 21: Drug – exposome interactions
- Session 22: Computational models to reliably predict chemical mixture toxicity
- Session 23: The value of micro-physiological systems for drug safety assessment – a series of case studies
- Session 24: Building confidence in the use of new approach methodologies for safety decision-making
- Session 25: Safeguarding female reproductive health across disciplines
- Session 26: Computational toxicology – New advances and acceptance in academia, industry and regulation
- Session 27: Predictive systems to identify etiological factors and pathogenic mechanisms of neurodegeneration
- Session 28: Preclinical immune-safety evaluation of immuno-oncology therapies
- Session 29: Is there a human risk to PFAS exposure?
- Session 30: Revisiting paracetamol-induced multisystem toxicity: novel mechanistic insights

Short Oral Communications

- Short Oral Communications I
- Short Oral Communications II
- Short Oral Communications III
- Short Oral Communications IV

Poster presentations

- P01: Adverse outcome pathways
- P02: Biomarkers of effect/exposure
- P03: Computational toxicology
- P04: In vitro methodologies & screening
- P05: In vitro to in vivo extrapolation (QIVIVE)
- P06: New approach methodologies: 3D models, stem cells, organ-on-a-chip, microfluidics
- P07: Omics in toxicology
- P08: Cardiovascular diseases
- P09: Clinical toxicology
- P10: Developmental neurotoxicology
- P11: Developmental toxicology
- P12: Epidemiological toxicological studies
- P13: Geno-toxicology & carcinogenesis
- P14: Immune toxicology
- P15: Liver toxicology
- P16: Metabolic toxicology
- P17: Reproductive toxicity
- P18: Systemic toxicology
- P19: Ecotoxicology
- P20: Environmental toxicology
- P21: Occupational toxicology
- P22: Regulatory toxicology (REACH)
- P23: Risk prediction and assessment /risk assessment using new approach methodologies
- P24: Gut microbiota and toxicity
- P25: Mixture toxicology
- P26: Toxicology in life cycle analysis

Late Breaking Abstracts

Abstracts of the
56th Congress of the European Societies of Toxicology
(EUROTOX 2021)
TOXICOLOGY OF THE NEXT GENERATION

Virtual Congress, 27th September – 1st October 2021

Scientific Programme Committee (SPC)

- Prof. Félix Carvalho,
SPC Chair
- Prof. Mümtaz İřcan,
EUROTOX Executive Member
- Dr. Thomas Weiser,
EUROTOX Industry Executive Member
- Prof. Heather Wallace,
SPC Special Guest (ADD)
- Chairs of the EUROTOX Speciality Sections:
Prof. Doris Marko,
Carcinogenesis
Prof. Valentina Galbiati,
Immunotoxicology & Chemical Allergy
Prof. Hilmi Orhan,
Molecular Toxicology
Dr. Georges Kass,
ERAS Risk Assessment
Prof. Mathieu Vinken,
In Vitro and in Silico Toxicology (IN2TOX SS)
- Dr. Lucija Perharič,
2023 Ljubljana Congress Delegate
- Prof. Eva Bonefeld-Jørgensen,
2024 Copenhagen Congress President
- Prof. Anne Marie Vinggaard,
2024 LOC Copenhagen Congress Delegate

Organising Committee

- Prof. Heather Wallace,
Chair, EUROTOX President
- Prof. Félix Carvalho,
EUROTOX President-Elect
- Prof. Mümtaz İřcan,
EUROTOX Past-President
- Dr. Thomas Weiser,
EUROTOX Treasurer
- Prof. Dr. Martin Wilks,
EUROTOX Secretary-General

Reviewers

The abstracts of poster presentations and short oral communications were peer-reviewed by the following reviewers:

- Félix Carvalho,
Chair of the Scientific Programme Committee
- Heather Wallace,
EUROTOX President
- Emanuela Corsini,
EUROTOX Executive Committee Member
- Theo de Kok,
EUROTOX Executive Committee Member
- Mümtaz İřcan,
EUROTOX Executive Committee Member
- Mattias Öberg,
EUROTOX Executive Committee Member
- Joao Paulo Teixeira,
EUROTOX Executive Committee Member
- Thomas Weiser,
EUROTOX Executive Committee Member
- Martin Wilks,
EUROTOX Executive Committee Member
- Doris Marko,
Chair of the EUROTOX Carcinogenesis Speciality Section
- Jan Vondracek,
Secretary General of the EUROTOX Carcinogenesis Speciality Section
- Valentina Galbiati,
Interim Chair of the EUROTOX ITCASS Speciality Section
- Hilmi Orhan,
Chair of the EUROTOX Molecular Toxicology Speciality Section
- Mathieu Vinken,
Chair of the EUROTOX In Vitro and In Silico Toxicology Speciality Section (IN2TOX SS)
- Georges Kass,
Chair of the EUROTOX ERASS Speciality Section

Organising Society



Sponsors and Exhibitors of the
56th Congress of the European Societies of Toxicology
(EUROTOX 2021)
TOXICOLOGY OF THE NEXT GENERATION

Virtual Congress, 27th September – 1st October 2021

S P O N S O R S

Silver Sponsors



Bronze Sponsors



Sponsors



methods for preliminary studies without animal in order to reduce the number of animal studies and increase the quality of studies. In our project, we have developed an *in vitro* 3D model anatomical model of the macaque airway. We use a high precision CT-scans of Non-Human Primates and the 3D printing technique with stereolithography method.

We have developed a refined *in vitro* 3D Cast model, which accurately mimics the upper airway of 3 macaques and the lower airway down to the second bronchial division.

However, the 3D model needs to be validated. To validate this model, a comparative study between the aerosol deposition obtained with the 3D model and the deposition obtained with the three macaques was carried out by scintigraphy imaging. Aerosols will be generated using three nebulizers generating three different particle sizes in order to target and study three different deposition areas in the airways: the first nebulizer with a 10µm in terms of Volume Median Diameter (VMD) predicting a major deposition in the upper airways (90%), the second nebulizer with a 1, 35µm in terms of Mass Median Aerodynamic Diameter (MMAD) predicting a deposition in upper and lower airways (50%) and the third with a 0, 36µm of MMAD predicting a major deposition in lower airways (90%).

If the 3D model is validated by the comparison between *in vitro* and *in vivo* results in terms of scintigraphy deposition measurement, it will allow to reduce the number of experiments on macaques and will participate to the improvement of the quality of studies.

LP-06

Genotoxicity and inflammatory potential of stainless steel welding fume particles – an *in vitro* study on standard vs Cr(VI)-reduced flux-cored wires and the role of released metals

*S. McCarrick¹, V. Romanovski^{2,3,4}, Z. Wei^{4,5}, E. M. Westin⁶, K.-A. Persson⁷, K. Trydell⁷, R. A. Wagner⁸, I. Odnevall^{4,9,10}, Y.S. Hedberg^{4,5,11}, H. L. Karlsson¹

- 1 Karolinska Institutet, Institute of Environmental Medicine, Stockholm, Sweden;
- 2 National University of Science and Technology – MISIS, Center of Functional Nano-Ceramics, Moscow, Russia;
- 3 National Academy of Sciences of Belarus, Institute of General and Inorganic Chemistry, Minsk, Belarus;
- 4 KTH Royal Institute of Technology, Department of Chemistry, Division of Surface and Corrosion Science, Stockholm, Sweden;
- 5 The University of Western Ontario, Department of Chemistry, London, Ontario, Canada;
- 6 voestalpine Böhler Welding GmbH, Kapfenberg, Austria;
- 7 Swerim, Kista, Sweden;
- 8 Linde GmbH/UniBw, Munich, Germany;
- 9 Karolinska Institutet and KTH Royal Institute of Technology, AIMES – Center for the Advancement of Integrated Medical and Engineering Sciences, Stockholm, Sweden;
- 10 Karolinska Institutet, Department of Neuroscience, Stockholm, Sweden;
- 11 The University of Western Ontario, Surface Science Western, London, Ontario, Canada

Welders are a large occupational group exposed to metal-containing particles in the fumes generated during the welding process. Exposure to welding fumes has been linked to several respiratory health effects which serves as a driving force to develop new methods that generate less toxic fumes. The individual contribution of the various metals found in welding fumes is not fully understood, but the carcinogen hexavalent chromium (Cr(VI)) has been proposed to be largely involved in the toxicity of stainless steel welding fumes. To explore the role of released metals for welding particle-induced toxicity and test the hypothesis that a reduction of the Cr(VI) content in

the fumes of FCWs results in welding fume particles less hazardous to welders, we compared the toxicity of stainless steel welding fume particles generated with standard flux cored-wire (FCWs) electrodes to those generated with Cr(VI)-reduced FCWs *in vitro*. The endpoints of cell viability, DNA damage and inflammation were examined using human bronchial epithelial cells (HBEC-3kt) and human monocyte derived macrophages (THP-1) as models. To elucidate the role of particles versus released metals, the cells were exposed to either the welding fume particles or solely its released metal fraction. The welding fume particles generated with Cr(VI)-reduced FCWs released small levels of Cr(VI), indicating a successful development and they were further found to be considerably less cyto- and genotoxic compared to the those of standard FCWs. The released fraction of the fumes generated with standard FCWs, being predominantly Cr(VI), was concluded to be toxic and may therefore explain a large part of the cytotoxicity and DNA damage observed in response to the particles. In contrast, an increase in the release of inflammatory cytokines was observed in response to all welding fumes, independent of Cr(VI)-reduction. The released metal fractions of the welding fumes did not induce similar inflammatory effects as the particles, indicating this endpoint not to be dependent on the release of Cr(VI). In conclusion, these results suggest the release of Cr(VI) to be at least partly responsible for the acute toxicity of standard FCW generated stainless steel welding fumes. This suggests a potential benefit of substituting standard FCWs with Cr(VI)-reduced wires to reduce the toxicity of the welding fumes and improve the occupational environment of welders.

LP-07

How maternal exposure to aflatoxin B1 impacts the development of progeny intestinal immune system

P. Bastos-Amador^{1,4}, E. L. Duarte^{2,3}, P. Alvito^{4,5}, R. Assunção^{5,4}, *M. Ferreira^{6,1}

- 1 Champalimaud Foundation, Champalimaud Centre for the Unknown, Lisbon, Portugal;
- 2 University of Évora, School of Science and Technology, Évora, Portugal;
- 3 MED-Mediterranean Institute for Agriculture, Environment and Development, Évora, Portugal;
- 4 National Institute of Health Dr. Ricardo Jorge, Food and Nutrition Department, Lisbon, Portugal;
- 5 University of Aveiro, CESAM - Centre for Environmental and Marine Studies, Aveiro, Portugal;
- 6 University of Coimbra, Center for Neuroscience and Cell Biology, Coimbra, Portugal

Exposure to toxic contaminants during early-life is associated with the development of diseases. Individuals are exposed to mycotoxins since early stages of life^[1]. However how maternal exposure to mycotoxins influences the development and function of the offspring's immune system remains largely unexplored. Recently, we showed that *in utero* maternal exposure to micronutrients is critical for the development of the immune system, which sets long term immunity if the progeny^[2]. Here we show that presence of aflatoxin B1 in the diet of pregnant murine females affects the development and function of the intestinal immune system. Notably, maternal exposure to AFB1 promoted an increase of overall T cell population, while it also resulted in a selective reduction of cytokine-producing innate lymphoid cells group 2 (ILC2) population in intestine of the progeny. These alterations were associated with decreased expression of Reg3b, Reg3g and Fut2 by the intestinal mucosa of progeny. Thus, these results indicate that maternal exposure to mycotoxins impacts the development of offspring intestinal immune system. ILC2 are critical in intestinal epithelial repair, whether mice exposed to AFB1

display defective tissue damage response needs to be investigated. Also FUT2-dependent fucosylation is key in host–commensal symbiosis suggesting alterations in the intestinal microbiota. Our work reveals that maternal exposure to dietary contaminants such as mycotoxins alters the normal development of intestinal immune system framework of the progeny and may have impact in their immune function.

This work was funded by FCT/MCTES through national funds, to early-MYCO (PTDC/MED-TOX/28762/2017), and CESAM (UIDP/50017/2020+UIDB/50017/2020).

References

- [1] Assunção R, Vasco E, Nunes B, Loureiro S, Martins C, Alvito P. 2015, 'Single-compound and cumulative risk assessment of mycotoxins present in breakfast cereals consumed by children from Lisbon region, Portugal', *Food Chem Toxicol*, Dec;86, 274–81, DOI: 10.1016/j.fct.2015.10.017
- [2] van de Pavert SA, Ferreira M, 2014, 'Maternal retinoids control type 3 innate lymphoid cells and set the offspring immunity', *Nature*, Apr 3;508(7494), 123–127, doi: 10.1038/nature13158

LP-08

Test System of Gonadotoxic Activity Identification is more Sensitive and Informative than 3-generations Reproductive Toxicity Study in the Endocrine-Disruptor Mesotrione Research

*M. Prodanchuk, N. Shepelska, Y. Kolianchuk

L.I. Medved's Research Center of Preventive Toxicology, Food and Chemical Safety of the MoH of Ukraine, Kyiv, Ukraine

The mesotrione pesticide is one of the three main chemical classes of compounds - 4-hydroxyphenylpyruvate-dioxygenase inhibitors, namely the class of tricetones.

The mechanism of pesticide mesotrione action is determined by a violation of tyrosine metabolism, which during embryo- and fetogenesis periods can lead to eye and skin damage, mental retardation, and impaired motor coordination in children. This pesticide is an explicit endocrine-disruptor and is more dangerous for offsprings than for parental generation animals. Like most endocrine-disruptors that violate the endocrine activity of the thyroid gland, it can induce transgenerational epigenetic effects when exposed during gametogenesis.

In reproductive toxicity studies of mesotrione in three generations rats (1997), a lowest-observed-adverse-effect level (LOAEL) was established for reproductive toxicity at 2500 ppm (297.2 mg/kg body weight). No-observed-adverse-effect level (NOAEL) in this experiment was 100 ppm (11.7 mg/kg body weight). It should be emphasized that such important indicators as sperm parameters in males and the estrous cycle in females were not studied in this experiment.

We conducted studies of the mesotrione reproductive toxicity in the test-system of gonadotoxic activity identification. The test substance was administered to females (10 weeks) and males (11 weeks) before mating with intact animals (untreated). Based on the analysis of the results obtained, it was concluded that at a dose of 12.0 mg/kg body weight when exposed to males, the mesotrione has manifested antiandrogenic activity (a decrease in the total number of sperm, the number and percentage of motile sperm, an increase in the percentage of pathological forms of sperm, a decrease of conception and fertility indexes). When exposed to females, the estrous cycle disorder was observed (a decrease in the estrogen-dependent stage of proestrus).

NOAEL in this experiment is 0.3 mg/kg body weight.

Thus, in this test system, a greater sensitivity of males was found in comparison with females to the endocrine-disruptor effect of mesotrione when exposed during gametogenesis.

LP-09

Isoflucypram: A new fungicide with no thyroid related endocrine disrupting properties and an overall favorable mammalian safety profile

*H. Tinwell

Bayer SAS, Regulatory Toxicology, Lyon, France

Isoflucypram is a new cereal fungicide currently undergoing evaluation for European registration. Based on its extensive data package, isoflucypram is not genotoxic nor carcinogenic and has no developmental toxicity potential. Furthermore, although a delay in puberty was observed in the 2-generation study, isoflucypram has no overall impact on fertility or reproduction. As per EU Regulation 283/2013 the endocrine disrupting (ED) potential of isoflucypram was evaluated as part of the safety assessment package. As the liver (all species) and thyroid (rat only) are target organs of isoflucypram, the main focus of the ED evaluation was the mode of action (MoA) responsible for the minimal effects observed on the rat hypothalamus-pituitary-thyroid (HPT) axis and determining the human relevance of the perturbation of this axis.

A combination of standard repeat dose toxicity studies and short-term mechanistic investigations conducted in the rat demonstrated that isoflucypram is a marked hepatic enzyme inducer, most notably of the cytochrome P450s, Cyp3a and Cyp2b, and of UDP-glucuronosyltransferases (UDPGT; including T4-UDPGT). This increased enzyme activity was associated with increased liver weight and hepatocellular hypertrophy. In the same studies, minimal thyroid follicular cell hypertrophy was observed but only at doses where liver stimulation was already established. A slight, statistically significant, increase in thyroid stimulating hormone, with no concomitant decrease in T4, was recorded at the same dose level as that triggering follicular cell hypertrophy. Overall, the profile of observations was indicative of a liver mediated MoA giving rise to the minimal thyroid findings. The homeostasis of the HPT axis could, however, still be maintained as evidenced by the absence of clear effects on T4. Direct thyroid effects via thyroid peroxidase (TPO) and sodium iodide symporter (NIS) inhibition could be excluded providing further support for a liver mediated MoA. An *in vitro* comparison of hepatic enzyme induction conducted in rat and human hepatocytes confirmed the rat *in vivo* profile of increased Cyp3a, Cyp2b and T4-UDPGT activities. In contrast, marked quantitative differences were observed when comparing the rat and human responses, particularly for T4-UDPGT, where the basal and induced levels were 4-fold and up to 11-fold lower respectively in the human hepatocytes compared to those observed in the rat. The *in vivo* rat data demonstrate that the minimal perturbation of the HPT axis induced by isoflucypram was secondary to liver enzyme induction. Furthermore, the *in vitro* comparison of hepatic enzyme induction demonstrated marked species differences thus providing evidence that this MoA for isoflucypram is not relevant for humans. Overall, it can be concluded that this molecule is not an ED via the T-modality for mammals based on the weight of evidence derived from the *in vitro* and *in vivo* standard and mechanistic investigations.

LP-10

Development of a novel QSAR model for predicting the synergistic effect of binary mixtures of estrogen receptor agonists

*M. Seo, J. Choi, M. Na, J. Kim

Chemical Safety Research Center, Korea Research Institute of Chemical Technology (KRICT), Daejeon, South Korea

Worldwide, there are growing concerns about the potential health threat caused by endocrine-disrupting compounds (EDCs) manufactured in the chemical industry^[1,2]. Estrogenic EDCs can interact with estrogen receptors (ERs) and induce ER-mediated responses. In hu-